1,6-Diphosphate Fructose for Injection

1. Pharmacology: Dextrorotatory fructose 1,6-diphosphate (FDP) is an intermediate product of glycolysis. It regulates several enzymatic reactions in cells by activating phosphofructokinase, pyruvate kinase and lactate. Hydrogenase. The concentration of FDP in different cells is different. The concentration of FDP in human erythrocytes is 6-10mg/L cell. In vivo and in vitro biochemical studies have shown that pharmacological doses of FDP can act on cell membranes, promote cell uptake of potassium in circulation and stimulate the production of high-energy phosphate and 2,3-diphosphoglycerol in cells. In addition, FDP can reduce hemolysis of erythrocytes caused by mechanical trauma and inhibit the production of oxygen free radicals caused by chemical stimulation. Patients with chronic obstructive pulmonary disease (COPD) will experience malnutrition during the progression of the disease, which will affect respiratory muscle function. In COPD patients, there is a high correlation between hypophosphatemia and renal phosphate reabsorption disorder. Phosphate deficiency in respiratory and peripheral muscles is due to renal phosphate consumption caused by malnutrition or the use of theophylline, diuretics, glucocorticoids and beta-receptor agonists. Phosphorus is a component of cells (membrane phospholipids, nucleic acids, 2,3-bisphosphoglycerate, phosphoproteins). Phosphorus consumption induces changes in neuromuscular and myocardial functions, and can also explain respiratory muscle weakness and fatigue in patients with cachectic COPD. Inducing phosphate consumption with an experimental diet can reduce respiratory muscle function, and correcting phosphate levels can improve its function. Although the efficacy of phosphate supplementation for cachectic COPD patients is not certain, clinical trials have shown that FDP is beneficial for treatment, especially in strengthening respiratory muscle strength, as shown by improvements in PImax, PaO2 and tolerance. 2. Toxicology: Subacute toxicity: Studies have shown that rabbits and dogs have been intravenously injected with 100mg/kg or 200mg/kg FDP for 30 consecutive days without any functional, histological or pathological changes. Teratogenicity: Teratogenicity studies have shown that routine injections of 100mg/kg and 200mg/kg FDP to rabbits did not reveal pathological changes or fetal malformations during pregnancy.

The main ingredient is trisodium fructose 1,6-diphosphate.

White or light yellow powder.

FDP (fructose 1,6-diphosphate) is suitable for hypophosphatemia. Hypophosphatemia can occur in acute situations, such as blood transfusion, surgery under extracorporeal circulation, parenteral nutrition, and is also related to some chronic diseases, such as chronic alcoholism, long-term malnutrition, chronic respiratory failure, and depletion of phosphoric acid.

Dosage: The recommended dose is 1-2 bottles per day. The dose for treating hypophosphatemia should be based on the degree of phosphate deficiency to avoid phosphate overload. For larger doses, it is recommended to take the drug twice a day. The dose for children should be based on body weight (70-160 mg/kg) and should not exceed the recommended dose.

When the intravenous infusion rate exceeds 10ml/min, the patient complains of blushing, palpitations, and tingling in the hands and feet. If adverse reactions occur, the patient should inform the doctor. Reports of allergic reactions and anaphylactic shock are rare. If an allergic reaction occurs, the drug should be stopped immediately and anti-allergic treatment should be given. Rescue measures for anaphylactic shock: stop taking the drug, monitor blood pressure, conduct shock-related treatment, and intravenously inject epinephrine, antihistamines, etc.

People who are allergic to fructose, hyperphosphatemia and renal failure.

Precautions for children: Depending on the doctor's evaluation of the child's clinical status, the doctor should weigh the pros and cons. Precautions for pregnancy and lactation: There are no adverse effects of FDP treatment in women in the last 3 months of pregnancy.

FDP should not be used with drugs that are insoluble between pH 3.5 and 5.8, nor with alkaline solutions containing high calcium salts.

Store tightly closed at room temperature.

5g/bottle

60 months